A recent meta-analysis involving 41 clinical trials and 6664 patients with advanced solid tumors investigated the predictive value of tumor and tumor-infiltrating immune cell PD-L1 expression by IHC assays such as Dako 28-8, Dako 22C3, Ventana SP142, Ventana SP263, and Dako clone 73-10 and demonstrated that PD-L1 expression was predictive of tumor response across all tumor types (odds ratio (OR) 2.26, 95% confidence interval (CI) 1.85-2.75, p < 0.001) [58]. The gene discussed is CD274; the disease is neoplasm.